Drug Sponsors

Science 37 to launch clinical trial research operating model

Friday, October 23, 2015

Science 37, a Los Angeles-based technology-enabled clinical research company, has completed a $6.5 million Series A financing co-led by Lux Capital and dRx Capital. The investment will accelerate Science 37’s development and rollout of its new operating model, which is designed to solve some of the greatest inefficiencies in conducting clinical trials.

[Read More]

Vaccine Center of Innovation launches

Thursday, October 22, 2015

In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.

[Read More]

Biogen to cut 11% of jobs

Thursday, October 22, 2015

Cambridge, Mass.-based Biogen has announced a corporate restructuring that includes the termination of a number of pipeline programs and an 11% reduction in workforce. The changes are expected to reduce the current annual run rate of operating expenses by about $250 million. The company plans to reinvest the savings to support key commercial initiatives, including increased sales and marketing activities behind TECFIDERA, and the advancement of high-potential pipeline candidates in areas such as Alzheimer’s disease, multiple sclerosis and spinal muscular atrophy.

[Read More]

Thermal Gradient moving to Virginia

Wednesday, October 21, 2015

Thermal Gradient, a developer of devices and systems for rapid molecular diagnostics, has chosen to relocate its operations from Rochester, N.Y., to the Richmond Region in Virginia. The molecular diagnostics solutions company recently leased a 10,000-square-foot-building to become a resident business in the Virginia Biotechnology Research Park in Richmond.

[Read More]

BioXcel, Pronutria ink data partnership

Wednesday, October 21, 2015

BioXcel, a Branford, Conn.-based global provider of cloud-based big data platforms, has partnered with Cambridge, Mass.-based Pronutria Biosciences to identify diseases characterized by high unmet need for therapies and nutritional products that are amenable to Pronutria’s novel technology platform. Pronutria is a biotechnology company pioneering a new class of products to mediate amino acid biology.

[Read More]

Daiichi Sankyo cuts 1,200 jobs

Monday, October 19, 2015

Daiichi Sankyo, based in Parsippany, N.J., will reorganize its U.S. commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology.

[Read More]

Adheron Therapeutics is acquired by Roche

Monday, October 12, 2015

Adheron Therapeutics has been acquired by Roche. Adheron is a privately held biotechnology company developing SDP051, a product that disrupts cell adhesion which can potentially be used to treat inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic disease. SDP051 was fully humanized using Abzena’s Composite Human Antibody technology.

[Read More]